Methamphetamine: Difference between revisions

Nav

(View all pending changes)

[checked revision]

← Older edit Newer edit →

VisualWikitext

@@ Line 1: / Line 1: @@
 {{MedTemplate
-| generic            = Methamphetamine
+| generic           = Methamphetamine
-| brand              = Desoxyn
+| brand             = Desoxyn
-| structure          =
+| structure         =
-| classes            = Amphetamine, Psychostimulant
+| classes           = Psychostimulant, Amphetamine
-| mechanism          = Potent monoamine releasing agent
+| uses              = <vote slug="inattention-meth">Inattention</vote>, <vote slug="hyperactivity-meth">Hyperactivity</vote>, <vote slug="obesity-meth">Obesity</vote>
-| uses               =
+| starting_dose     = 5 mg PO
-| starting_dose      =
+| preparations      = Desoxyn 5 mg tabs
-| preparations       =
+| fda_max           = 25 mg/day (ADHD per Desoxyn label); 15 mg/day (obesity, short-term, per Desoxyn label)
-| fda_max           =
+| routes            = Oral (prescribed)
-| routes             =
+| onset             =
-| onset              =
+| duration          =
-| duration           =
+| halflife          =
-| halflife           =
+| bioavailability   =
-| bioavailability    =
+| pregnancy         = Category C (per Desoxyn label)
-| pregnancy          =
+| legal             = Schedule II
-| legal              =
+| mechanism         = Monoamine releasing agent — TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport
-| intro              =
+| intro             = '''Methamphetamine''' is a CNS stimulant of the amphetamine class. It is FDA-approved (as '''Desoxyn''') for attention-deficit hyperactivity disorder and short-term management of obesity. It is a Schedule II controlled substance in the United States.
-| pharmacokinetics   =
+| indications       = <indication slug="adhd" title="ADHD in children, adolescents, and adults" author="MDElliottMD"/>
-| pharmacodynamics   =
+<indication slug="obesity" title="Obesity (short-term)" author="MDElliottMD"/>
-| indications        =
+| dosing            = <titration slug="adhd-desoxyn" title="ADHD — per Desoxyn label" author="MDElliottMD">
-| dosing             =
+Per the Desoxyn prescribing information, see the official label for current dosing guidance.
-| effects            =
+</titration>
-| contraindications  =
+| effects           =
-| interactions       =
+* <effect ref="attention" author="MDElliottMD"/>
-| pregnancy_details  =
+* <effect ref="wakefulness" author="MDElliottMD"/>
-| monitoring         =
+* <effect ref="motivation" author="MDElliottMD"/>
-| counseling         =
+* <effect ref="euphoria" author="MDElliottMD"/>
-| anecdotes          =
+* <effect ref="decreased-appetite" author="MDElliottMD"/>
-| seealso            =
+* <effect ref="dry-mouth" author="MDElliottMD"/>
-| references         =
+* <effect ref="hr-bp-elevation" author="MDElliottMD"/>
+* <effect ref="insomnia" author="MDElliottMD"/>
+* <effect ref="irritability" author="MDElliottMD"/>
+* <effect ref="anxiety" author="MDElliottMD"/>
+* <effect ref="headache" author="MDElliottMD"/>
+* <effect ref="weight-loss" author="MDElliottMD"/>
+* <effect ref="palpitations" author="MDElliottMD"/>
+* <effect ref="bruxism" author="MDElliottMD"/>
+* <effect ref="stereotypies" author="MDElliottMD"/>
+* <effect ref="agitation" author="MDElliottMD"/>
+* <effect ref="psychosis" author="MDElliottMD"/>
+* <effect ref="mania" author="MDElliottMD"/>
+* <effect ref="dependence" author="MDElliottMD"/>
+* <effect ref="tolerance" author="MDElliottMD"/>
+* <effect ref="cardiac-event" author="MDElliottMD"/>
+* <effect ref="seizure" author="MDElliottMD"/>
+* <effect ref="hyperthermia" author="MDElliottMD"/>
+* <effect ref="serotonin-syndrome" author="MDElliottMD"/>
+* <effect ref="withdrawal" author="MDElliottMD"/>
+| pk_absorption     =
+| pk_distribution   =
+| pk_metabolism     = Hepatic metabolism includes N-demethylation to amphetamine (an active metabolite).
+| pk_elimination    = Urinary elimination is pH-dependent.
+| pharmacodynamics  = Methamphetamine acts at monoaminergic terminals as a releasing agent via TAAR1 agonism, VMAT2 substrate activity, and DAT/NET reverse transport. Secondary mechanisms include weak monoamine reuptake inhibition.
+| contraindications = Per Desoxyn label:
+* Advanced arteriosclerosis
+* Symptomatic cardiovascular disease
+* Moderate to severe hypertension
+* Hyperthyroidism
+* Known hypersensitivity to sympathomimetic amines
+* Glaucoma
+* Agitated states
+* History of drug abuse (per label wording)
+* Concurrent MAOI use, or within 14 days of MAOI discontinuation
+| interactions      = * '''MAOIs''' — contraindicated (per label)
+* '''Acidifying agents''' — increase urinary clearance
+* '''Alkalinizing agents''' — decrease urinary clearance
+| pregnancy_details = Category C per Desoxyn label.
+| monitoring        =
+| counseling        =
+| anecdotes         =
+| seealso           = [[Mixed amphetamine salts]], [[Dextroamphetamine]], [[Lisdexamfetamine]], [[Methylphenidate]], [[Dexmethylphenidate]], [[Modafinil]]
+| references        = <references/>
 }}
 [[Category:Psychostimulants]]

MDElliottMD (talk | contribs)